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Methods: Thirty-two SSc patients underwent a cardiac MRI with dedicated lung
scanning and chest HRCT on the same day. One-hundred-thirty-five regions of
interest (ROIs) were identified, and STIR and T1 sequences were acquired[before
(T0) and after 5 (T5), 10 (T10) and 15 (T15) minutes from gadolinium injection].
The ROIs were classified according to HRCT as normal, dependent areas (prob-
ably related to blood pooling in supine position) and pathological areas(ground
glass ±reticulation on HRCT). Mean STIR and T1 times were also calculated for
each patients, and correlated with FVC, DLco, B-lines on lung ultrasound and
HRCT semi-quantitative scoring (Scleroderma Lung Study score). Patients were
followed-up and lung worsening was defined on the basis of clinical judgement
and at least >15% DLco decline.
Results: Mean STIR and mean T1 times were significantly different between nor-
mal, dependent and pathologic areas (p<0.001 between groups). Patients’ mean
STIR showed a significant correlation with DLco (R=0.56, p<0.01), HRCT Scle-
roderma Lung Study score (R=0.52, p<0.01) and B-lines on lung ultrasound
(R=0.63, p<0.01). The mean STIR of the 10 patients who developed a worsening
pulmonary involvement had significantly different MRI signal intensity in compari-
son to the 25 patients without worsening pulmonary involvement (125±46 vs 66
±37 msec, p<0.01).
Conclusions: Our data highlight the usefulness of lung MRI in SSc patients to dif-
ferentiate normal, dependent and pathologic areas, without need for contrast
medium administration, and with good correspondence to other functional and
imaging parameters. STIR values may have prognostic implications to predict
lung worsening. Lung MRI, although still very preliminary, is a promising imaging
tool that in the future may integrate HRCT in SSc-related ILD.
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Background: Kidney injury in mixed connective tissue disease (MCTD) is an
uncommon manifestation. Prevalence has been reported to be <4% in some
cohorts. The frequency of renal involvement in Hispanic patients with MCTD is not
known.
Objectives: We aimed to describe the prevalence, clinical characteristics and
outcomes of renal involvement in Mexican patients with MCTD.
Methods: We conducted a retrospective single-centre study. We included
patients with a diagnosis of MCTD according to the Alarcón-Segovia criteria who
regularly attended to a referral centre in Mexico City (2003–2017) and we identi-
fied those with renal involvement defined as proteinuria >500 mg/d with or without
active sediment, creatinine elevation 50% above baseline or development of glo-
merular filtration rate (GFR) <60 ml/min, with no other known cause. We collected
demographics, clinical manifestations, follow-up time, treatment, outcomes and
damage (SLICC/ACR-DI), renal function, serological and histological variables.
Results: One hundred and thirty one patients with MCTD were followed at our
centre. We identified 14 patients with renal involvement with a prevalence of
10.7%. Among those patients, 13 were women (92.8%); mean age at onset of
renal involvement was 44±8 years. Most frequent manifestations were Raynaud’s
phenomenon in 13 (92.8%) patients, arthritis in 12 (85.7%), puffy hands in 12
(85.7%), sclerodactily in 8 (77.1%), sicca syndrome in 8 (77.1%) and myositis in 7
(50%). Median time elapsed from MCTD diagnosis to renal involvement was 83
(2–365) months. In 3 patients, renal involvement was present at MCTD onset.
Seven (50%) patients had other signs of MCTD activity at the time of renal involve-
ment onset. Four (28.5%) patients presented with sub- nephrotic proteinuria, 3
(21.4%) with nephrotic range proteinuria and kidney injury, 2 (14.3%) with sub-
nephrotic proteinuria and kidney injury, 2 (14.3%) with nephrotic range proteinuria,
1 only with nephrotic range proteinuria and 1 (7.1%) with end-stage renal disease.
Microscopic hematuria was present in 9 (64.3%) patients and leukocyturia in 6
(42.8%). Renal biopsy was performed in 8 (57%) patients; pathological diagnoses
were: crescentic and necrotizing glomerulonephritis (GN) (2 patients; one of these
patients developed positive ANCA antibodies), GN ISN/RPS 2003 class III+V,1 GN
ISN/RPS 2003 class III+V with thrombotic microangiopathy,1 GN ISN/RPS 2003
class IV+V and vasculopathy,1 membranous GN,1 minimal mesangial GN1 and
chronic tubulointerstitial nephritis with vasculopathy.1 Ten (71.4%) patients
achieved either total or partial remission at a median follow up of 82 (1–367)
months. Only one patients required dialysis. At last follow up the median SLICC/
ACR-DI was 1.5 (0–4) points. Two patients died.
Conclusions: In our cohort of MCTD patients, prevalence of renal involvement
was low, although higher than the one reported in other populations. Clinical pre-
sentation and pathological diagnoses were diverse. Renal biopsy was helpful,
since glomerulonephritis, vasculopathy and overlap with ANCA associated
vasculitis were found in several patients; these options should be considered in
the differential diagnoses of MCTD patients with renal involvement.
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Objectives: In this study, we aimed to assess clinical features, poor prognostic
factors and survival analysis of patients with Idiopathic inflammatory myopathy
(IIM).
Methods: Records of 110 patients with IIM that had at least 6 months of follow-
up, fulfilling Bohan and Peter’s criteria were analysed for this study. Survival anal-
ysis was done by using Kaplan Meier method andmultiple “Cox” regression analy-
sis was applied to calculate the effect of multipl factors.
Results: Sixty-eight percent of 110 patients was female, the mean age of the
patients was 46 years, and the average follow up time was 77.5 months. Diagno-
sis of these patients was dermatomyositis (DM) in 68%, polymyositis (PM) in 26%,
autoimmune necrotizing autoimmune myopathy (NOM), inclusion body miyositis
(IBM) 6%. The percentage of periungual erythema, arthritis, dysphagia, respira-
tory muscle involvement and interstitial lung disease(ILD) 56, 22, 24, 32, 11 and
30. Malignancy was identified in 26% of patients. The percentages of malignan-
cies diagnosed at the time of diagnosis, before the diagnosis and during the fol-
low-up were 3.6, 11.8 and 8.2. The most frequent malignancy was breast cancer.
Others are carcinoma of gastrointestinal tract, lung, and genitourinary tract. ANA
was present in 36% and 12% of patients was positive for anti-Jo-1 antibody. The
average daily dose of prednisolone was 7.5 mg, the average usage time was 35.5
months. Causes of death were aspiration pneumonia-sepsis (50%) and malig-
nancy (25%). Significant associations with mortality was found between systemic
symptoms, periungual erytema, respiratory muscle involvement, dysphagia, pres-
ence of malignancy. Mortality was higher in ANA negative patients (p<0.001),
Five and 10 year survival in these patients were 83% and 75%. Five year survival
rate in patients with respiratory muscle involvement was 38% and 68% in those
with dysphagia. The presence of systemic symptoms, and malignancies were
identified as risk factors for mortality in multivariable analysis.
Conclusions: ILD and malignancies are frequent in our IIM cohort. Malignancies
are mostly detected at diagnosis. The mortality rate was high and the most com-
mon cause was infection. 10 year survival rate was 79%. Malignancy, respiratory
muscle involvement, dysphagia, negative ANA have a detrimental effect survival
in IIM patients.
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Background: Systemic sclerosis (SSc) is an immune-mediated disorder charac-
terised by abnormal fibrosis and diffuse microangiopathy with skin and internal
organ involvement. Interstitial lung disease (ILD) represents one of the most chal-
lenging complication of SSc, difficult to manage and correlate with a poor progno-
sis. Chest Computed Tomography (CT) is the gold standard for detection and
evaluation of SSc-ILD by means of semi-quantitative scoring of extent of lung
involvement. Some preliminary data suggest that rituximab (RTX) may be usefully
employed in the treatment of SSc patients.
Objectives: To investigate the role and effect of RTX on ILD in our SSc patients’
series.
Methods: We retrospectively evaluated a series of 18 SSc patients (M/F 6/12,
mean age 54.6±17.6 SD years, mean disease duration 11.4±6.5 SD years, L/D
cutaneous subsets 6/12) who received one or more cycles of RTX (4 weekly infu-
sions of 375 mg/m2) every 6 months for a total of 1–6 cycles. Lung involvement
was studied by means of pulmonary function tests (PFTs) (18/18) and inspiratory
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chest CT (10/18) before and after treatment. In particular, we considered PFTs
performed 6 months before RTX, at time 0, one year after the first RTX cycle, and
at the end of follow-up (13.7±7.3 years). ILD extent score was assessed by the
semi-quantitative method proposed by Goh et al (2008).1
Results: Forced vital capacity (FVC%) significantly reduced during the year
before RTX treatment [from 95.2±17.4 to 84.8±16.4; p=0.0017], as well as the dif-
fusing capacity for carbon monoxide (DLCO%) [from 58.1±14.3 to 47.6±12.9;
p=0.0002]. Conversely, FVC% and DLCO% stabilised one year after the first RTX
cycle (80.8±23 and 47.8±15.7, respectively), and at the end of the follow-up (84.3
±24.6 and 54.8.8±12.3, respectively; p=0.0001). In our cohort, only 7/10 patients
had ILD detectable on CT before treatment. At the end of the follow-up we
observed that ILD extented in 6/7 cases one patient remained stable, the three
subjects without ILD did not developed pulmonary fibrosis.
Conclusions: According to PFTs results, our study showed that RTX could stabi-
lise the progression of lung function tests in SSc patients. However, the semi-
quantitative visual score identified radiological pulmonary worsening in many
patient with stabilised PFTs. Therefore, the correlations between functional and
radiological outcomes are so weak that many Authors suggested they should be
considered together in SSc-ILD assessment.
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DIAGNOSTIC OF MACROVASCULAR INVOLVEMENT IN
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Background: Macrovascular involvement in Systemic Sclerosis (SSc) is caused
by proliferation of vascular smooth muscle cells within the intima of arteries (neo-
intimal proliferation). The resulting decrease in arterial volume is responsible for
the severity of Raynaud’s and for the onset of severe clinical manifestations such
as Renal Crisis and Pulmonary Artery Hypertension.
Several RCTs have demonstrated the efficacy of Endothelin Receptor Antago-
nists (ERAs) in targeting neointimal proliferation, which makes them to date, the
only disease modifying agent available in SSc. Nevertheless, the lack of validated
early diagnostics means the intention to treat with ERAs remains limited to the
diagnosis of end stage clinical manifestations of neointimal proliferation, such as
presence of Digital Ulcer (DU) and PAH.
Objectives: Here we aimed to determine the proof of concept validity of auto-
mated Digital Artery Volume Index (DAVIX) measured by non-contrast Time of
Flight (TOF) MRI as an objective diagnostic tool to be used as surrogate outcome
measure of neointimal proliferation in SSc.
Methods: 10 Healthy Volunteers (HV) and 8 SSc patients were enrolled. Six
patients underwent longitudinal assessments at least 12 months apart. MRI scans
were performed on a 3T Magnetom Verio (Siemens) and consisted of a VIBE 3D
T1 scan and a 2D TOF sequence of 8 min. DAVIX was calculated as the percent-
age of the ratio of digital artery and the respective finger volumes. The vessels
and fingers were manually outlined by an expert radiologist and used as a ‘gold
standard’ (DAVIX-1) and compared to a 2nd independent radiologist assessment
(DAVIX-2). An automated segmentation algorithm was developed using threshold
based segmentation and region growing (DAVIX-A) and validated against gold
standard. Intraclass correlation coefficient (ICC) and absolute agreement were
calculated to estimate reliability. Bland-Altman bias and 95% limits of agreement
(LoA) were calculated as well.
Results: SSc patients and HV had comparable age (44±8 vs 45±8) and gender
(F:M=5:2 vs 4:2). 4 fingers were affected by DUs at baseline and two fingers were
affected by new DU at follow up. Mean(±SD) DAVIX in HV was 1.21 (±0.39) with
no significant difference among individual fingers. Mean DAVIX in SSc patients
was 0.37 (±0.18) and 0.32 (±0.39) at baseline and follow-up, respectively
(p<0.0001 vs HV for both). The fingers with DU had an average DAVIX of 0.24
(±0.08) vs 0.40 (±0.18) of the fingers without DU (p=0.02). DAVIX changed over
time in both directions. In the fingers affected by new DU, DAVIX dropped by 56%
(0.161 vs 0.072) and 86% (1.149 vs 0.132), respectively. ICC among two inde-
pendent readings was 0.90 (95% LoA 0.139, 0.118) with overall r2=0.74
(p<0.0001). Automated segmentation showed superior correlation to gold stand-
ard with r2=0.80 (p<0.0001).
Conclusions: This proof of concept study demonstrated validity and sensitivity to
change of DAVIX for the automated volumetric assessment of digital arteries,
which reflected clinical worsening in patients with new DU. Larger, longitudinal
studies are planned to assess DAVIX’ predictive value for the onset of DU and its
potential use as early diagnostic of neointimal proliferation in SSc.
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Background: Periostin(PN), a matricellular protein, serves as a regulator of
wound healing and fibrosis. PN-/- mice develop lower degrees of fibrosis when
exposed to bleomycin(BLM), suggesting a possible role in the pathogenesis of
Systemic Sclerosis(SSc)1. PN serum levels are increased in SSc and seem to be
associated with skin disease severity2.
Objectives: To evaluate the role of serum PN as a biomarker of SSc severity,
and to determine PN tissue expression in SSc patients.
Methods: PN serum levels were assessed by ELISA in 48 patients: 3 primary
Raynaud’s, 12 early SSc, 11 SSc without organ involvement, 22 SSc with organ
involvement. All SSc patients met 2013 ACR/EULAR criteria. PN serum levels
were evaluated in 28 sex-/age-matched healthy-controls(HCs). Data regarding
disease subtypes and organ involvement were correlated. PN skin expression
was determined by immunohistochemistry on paired involved and uninvolved skin
biopsy samples in 10 patients(4 lcSSc and 6 dcSSc) in combination with a-SMA,
CD68, CD3, CD4, CD8, CD163, CD20 and CD131.
Results: PN serum levels were higher in SSc patients compared to HCs(32.7
±8.0 vs 27.7±7.3 ng/ml, p<0.001). Its levels were comparable among different
groups. No differences in PN serum levels were detected when comparing dis-
ease subtypes, disease duration, presence and extent of organ involvement,
autoantibodies profile and current or previous treatment. Higher PN levels were
found in SSc patients with active pattern at nailfold videocapillaroscopy and a his-
tory of digital ulcers(p<0.02). PN serum levels did not correlate with skin or lung
disease extent. Skin samples from involved SSc skin showed high PN expression
in the upper dermis and in the fibrotic area of the lower dermis(more evident in
dcSSc), suggesting a role in skin fibrosis. In all SSc involved skin, PN was
expressed in areas where ongoing fibroproliferation and macrophage/T lympho-
cytic infiltration occured, indirectly suggesting a pathogenic role in inflammation
driven-fibrosis. Interestingly, an identical PN immunohistochemical expression
was evident in uninvolved dcSSc skin, but not in lcSSc skin.
Conclusions: In our cohort PN serum levels are elevated in SSc patients but
they do not correlate with disease features. Its postulated role as a severity bio-
marker needs to be further elucidated. The different immunohistochemical
expression of PN in uninvolved skin from dcSSc and lcSSc patients suggests a
possible pathogenic role in the progressive inflammation-driven fibrosis that char-
acterise diffuse cutaneous involvement.
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FRI0445 A RANDOMISED CONTROLLED TRIAL TO COMPARE
THE EFFICACY OF ORAL MYCOPHENOLATE MOFETIL
WITH PLACEBO IN PATIENTS WITH SYSTEMIC
SCLEROSIS RELATED EARLY INTERSTITIAL LUNG
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Background: Previous studies showed benefit of immunosuppressants in mod-
erate to severe ILD in systemic sclerosis (SSc).1,2 Initiation of immunosuppres-
sion early in the course of SSc-ILD might help in halting disease process and
improve long termmorbidity and mortality.
Objectives: Aim of the study was to determine efficacy and safety of mycopheno-
late mofetil (MMF) in treating early and mild SSc-ILD (ILD on HRCT, FVC 70%
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